Analysis of killer cell immunoglobulin-like receptor genotypes in acute and chronic myeloid leukemia

Merve Erkoç; Emel Gürkan; Hüseyin Derya Dinçyürek; Suzan Dinkçi; Ozlem Goruroglu Ozturk; Eren Erken

Makale detayları

Analysis of killer cell immunoglobulin-like receptor genotypes in acute and chronic myeloid leukemia

Yazarlar:

Merve Erkoç | Emel Gürkan | Hüseyin Derya Dinçyürek | Suzan Dinkçi | Ozlem Goruroglu Ozturk | Eren Erken

Yayıncı:

Cukurova University

Ana Başlıklar:

Doğuştan Bağışıklık | Hematolojik Tümörler

Dergi:

Cukurova Medical Journal Vol.50 Issue 2, pp.496-505

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351449

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Purpose: Interactions between natural killer NK-expressed killer-cell immunoglobulin-like receptors KIRs and Major Histocompatibility Complex MHC class I molecules determine immune responses against tumour cells. Previous studies have shown that alloreactive potential of NK cells provide a promising treatment option for patients with hematological malignancies. The aim of this study was to investigate the KIR genes and genotypes in patients with acute myeloid leukemia AML and chronic myeloid leukemias CML. Materials and Methods: We investigated the frequency of KIR in AML n34 and CML n56 patients from Southern Mediterranean region of Türkiye and compared the results with 100 healthy controls. Polymerase chain reaction PCR and sequence-specific oligonucleotide SSO methods were used to identify KIR genes in peripheral blood samples. Results: We observed an increased frequency of inhibitory KIR2DL3 in myeloid leukemia patients 91.3 compared to controls 78. Additionally, the frequency of KIR2DL3 was significantly higher in CML patients compared to controls 93.5 vs. 78,. Notably, there was also a decreased incidence of inhibitory KIR2DL2 and its activating counterpart KIR2DS2 in CML patients compared to controls 34.8 vs. 52, both, respectively. Additionally, there was a tendency for inhibitory KIR genes to predominate in patients with myeloid leukemia. Conclusion: Our findings suggest a potential role for the KIR genes in the pathogenesis of myeloid leukemia. Further studies are needed to investigate the relationships between KIR gene polymorphisms and human leukocyte antigen HLA ligands in leukemia and the impact of NK cell responses on clinical outcomes.

 Purpose: Interactions between natural killer NK-expressed killer-cell immunoglobulin-like receptors KIRs and Major Histocompatibility Complex MHC class I molecules determine immune responses against tumour cells. Previous studies have shown that alloreactive potential of NK cells provide a promising treatment option for patients with hematological malignancies. The aim of this study was to investigate the KIR genes and genotypes in patients with acute myeloid leukemia AML and chronic myeloid leukemias CML. Materials and Methods: We investigated the frequency of KIR in AML n34 and CML n56 patients from Southern Mediterranean region of Türkiye and compared the results with 100 healthy controls. Polymerase chain reaction PCR and sequence-specific oligonucleotide SSO methods were used to identify KIR genes in peripheral blood samples. Results: We observed an increased frequency of inhibitory KIR2DL3 in myeloid leukemia patients 91.3 compared to controls 78. Additionally, the frequency of KIR2DL3 was significantly higher in CML patients compared to controls 93.5 vs. 78,. Notably, there was also a decreased incidence of inhibitory KIR2DL2 and its activating counterpart KIR2DS2 in CML patients compared to controls 34.8 vs. 52, both, respectively. Additionally, there was a tendency for inhibitory KIR genes to predominate in patients with myeloid leukemia. Conclusion: Our findings suggest a potential role for the KIR genes in the pathogenesis of myeloid leukemia. Further studies are needed to investigate the relationships between KIR gene polymorphisms and human leukocyte antigen HLA ligands in leukemia and the impact of NK cell responses on clinical outcomes.

 Purpose: Interactions between natural killer NK-expressed killer-cell immunoglobulin-like receptors KIRs and Major Histocompatibility Complex MHC class I molecules determine immune responses against tumour cells. Previous studies have shown that alloreactive potential of NK cells provide a promising treatment option for patients with hematological malignancies. The aim of this study was to investigate the KIR genes and genotypes in patients with acute myeloid leukemia AML and chronic myeloid leukemias CML. Materials and Methods: We investigated the frequency of KIR in AML n34 and CML n56 patients from Southern Mediterranean region of Türkiye and compared the results with 100 healthy controls. Polymerase chain reaction PCR and sequence-specific oligonucleotide SSO methods were used to identify KIR genes in peripheral blood samples. Results: We observed an increased frequency of inhibitory KIR2DL3 in myeloid leukemia patients 91.3 compared to controls 78. Additionally, the frequency of KIR2DL3 was significantly higher in CML patients compared to controls 93.5 vs. 78,. Notably, there was also a decreased incidence of inhibitory KIR2DL2 and its activating counterpart KIR2DS2 in CML patients compared to controls 34.8 vs. 52, both, respectively. Additionally, there was a tendency for inhibitory KIR genes to predominate in patients with myeloid leukemia. Conclusion: Our findings suggest a potential role for the KIR genes in the pathogenesis of myeloid leukemia. Further studies are needed to investigate the relationships between KIR gene polymorphisms and human leukocyte antigen HLA ligands in leukemia and the impact of NK cell responses on clinical outcomes.

 Amaç: Doğal öldürücü NK tarafından ifade edilen killer-cell immunoglobulin-like receptors KIRlar ile major doku uygunluk kompleksi MHC sınıf I molekülleri arasındaki etkileşimler, tümör hücrelerine karşı bağışıklık tepkilerini belirler. Önceki çalışmalar, NK hücrelerinin alloreaktif potansiyelinin hematolojik maligniteli hastalar için umut verici bir tedavi seçeneği sunduğunu göstermiştir. Bu çalışmanın amacı akut miyeloid lösemi AML ve kronik miyeloid lösemi KML hastalarında KIRgenlerini ve genotiplerini araştırmaktır. Gereç ve Yöntem: Türkiyenin güney Akdeniz bölgesinde AML n34 ve KML n56 hastalarında KIR sıklığı araştırıldı ve bu sonuçlar 100 sağlıklı kontrolle karşılaştırıldı. Periferik kan örneklerinden KIR genlerini tanımlamak için polimeraz zincir reaksiyonu PCR ve dizi spesifik oligonükleotid SSO yöntemi kullanıldı. Bulgular: Myeloid lösemi hastalarında 91,3 kontrollerle 78 karşılaştırıldığında inhibitör KIR2DL3ün artmış sıklığını gözlemledik. Ayrıca KIR2DL3 sıklığı KML hastalarında kontrol grubuna göre anlamlı derecede yüksekti 93,5e karşı 78. Özellikle KML hastalarında kontrollerle karşılaştırıldığında inhibitör KIR2DL2 ve onun aktive edici karşılığı olan KIR2DS2nin insidansında azalma da mevcuttu sırasıyla 34,8e karşı 52, her ikisi de. Ek olarak, myeloid lösemi hastalarında inhibitör KIR genlerinin baskın olma eğilimi mevcuttu. Sonuç: Bulgularımız miyeloid lösemilerin patogenezinde KIR genlerinin potansiyel bir rolüolduğunu göstermektedir. Lösemilerde KIR gen polimorfizmleri ile insan lökosit antijeni HLA ligandları arasındaki ilişkileri ve NK hücre yanıtlarının klinik sonuçlar üzerindeki etkisini araştıran daha fazla çalışma yapılması gerekmektedir.

Makale detayları

Analysis of killer cell immunoglobulin-like receptor genotypes in acute and chronic myeloid leukemia

Yazarlar:

Merve Erkoç | Emel Gürkan | Hüseyin Derya Dinçyürek | Suzan Dinkçi | Ozlem Goruroglu Ozturk | Eren Erken

Yayıncı:

Cukurova University

Ana Başlıklar:

Doğuştan Bağışıklık | Hematolojik Tümörler

Dergi:

Cukurova Medical Journal Vol.50 Issue 2, pp.496-505

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351449

pISSN:

2602-3032

Leukemia

KIR

myeloid

NK cell

genotypeLösemi

KIR

miyeloid

NK hücresi

genotip

Sayı

Makale detayları

Yazarlar: Merve Erkoç | Emel Gürkan | Hüseyin Derya Dinçyürek | Suzan Dinkçi | Ozlem Goruroglu Ozturk | Eren Erken

Yayıncı: Cukurova University

Ana Başlıklar: Doğuştan Bağışıklık | Hematolojik Tümörler

Dergi: Cukurova Medical Journal Vol.50 Issue 2, pp.496-505

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001351449

pISSN: 2602-3032

Sayı

Yazarlar:

Merve Erkoç | Emel Gürkan | Hüseyin Derya Dinçyürek | Suzan Dinkçi | Ozlem Goruroglu Ozturk | Eren Erken

Yayıncı:

Cukurova University

Ana Başlıklar:

Doğuştan Bağışıklık | Hematolojik Tümörler

Dergi:

Cukurova Medical Journal Vol.50 Issue 2, pp.496-505

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351449

pISSN:

2602-3032